会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Method of gene delivery using wildtype adeno associated viral (AAV)
vectors with insertions
    • 使用具有插入的野生型腺相关病毒(AAV)载体的基因递送方法
    • US6153436A
    • 2000-11-28
    • US4877
    • 1998-01-09
    • Paul L. HermonatJ. Gerald QuirkBrian BishopHan Li
    • Paul L. HermonatJ. Gerald QuirkBrian BishopHan Li
    • A61K48/00C12N15/864C12N15/86
    • C12N15/86A61K48/00C12N2750/14143
    • The present invention provides a method of human gene therapy using AAV vectors with essentially wildtype phenotype. Genes of 900 bases or less can be inserted into wildtype AAV and still allow the resulting vector to have a largely wildtype phenotype. For example, several antisense genes could be inserted and still allow packaging. Such wildtype vectors have several advantages. First, high titers of such vectors is easy to accomplish. Second, the vectors, since they include the Rep78 gene, integrate specifically into human chromosome 19. Third, such vectors, being wildtype, spread after their initial introduction. Another method for use of large wildtype AAV genomes is as complementors for fully defective AAV vectors. Such complementors can be delivered by virus infection and, be introduced easily into 100% of the cells used to produce virus. Viral infection is superior to synthetic techniques for introducing DNA into tissue culture producer cells. When large essentially wildtype AAV complementor virus are used in conjunction with AAV vector virus allowing for the introduction of both vectors into all cells, high titers of recombinant AAV virus is achieved.
    • 本发明提供使用基本上野生型表型的AAV载体的人基因治疗方法。 将900个碱基以下的基因插入到野生型AAV中,并且仍然允许所得载体具有很大的野生型表型。 例如,可以插入几个反义基因并仍然允许包装。 这种野生型载体具有几个优点。 首先,这种载体的高滴度很容易完成。 第二,载体,因为它们包括Rep78基因,特异性整合入人染色体19。第三,这种载体,野生型,在其初次引入后扩散。 使用大型野生型AAV基因组的另一种方法是完全缺陷的AAV载体的补体。 这样的补体可以通过病毒感染递送,并且容易地引入用于产生病毒的100%的细胞中。 病毒感染优于将DNA引入组织培养生产细胞的合成技术。 当大的基本野生型AAV补体病毒与AAV载体病毒结合使用时,允许将两种载体引入所有细胞,实现了高效价的重组AAV病毒。
    • 8. 发明申请
    • Adeno-associated virus AAV Rep78 major regulatory protein mutants thereof and uses thereof
    • US20080145339A1
    • 2008-06-19
    • US10969248
    • 2004-10-21
    • Paul L. Hermonat
    • Paul L. Hermonat
    • A61K35/76C12N7/01A61K38/00C12N15/00C12N15/09C12Q1/68A61P31/12A61K31/70C07H21/00C07K14/005
    • C12N15/86A61K38/00A61K48/00A61K2121/00C07K14/005C07K2319/00C12N2740/16322C12N2740/16334C12N2750/14122C12N2750/14143
    • AAV Rep78 mutants comprising a modified AAV Rep78 protein that possesses different biochemical and biological functions as compared to the wild-type AAV Rep78 protein are disclosed. Particularly, the AAV Rep78 mutants that bind to at least one of a papillomavirus DNA or an AAV DNA or an oncogene or HIV DNA differently as compared to the wild-type AAV Rep78 protein, assays to select such mutants, and pharmaceutical compositions containing the AAV Rep78 mutants are disclosed. The present invention further discloses DNA sequences encoding at least one AAV Rep78 mutant that possesses different biochemical and biological functions as compared to the wild-type AAV Rep78 protein and pharmaceutical compositions comprising the DNA sequences. The present invention additionally is directed to a method of inhibiting papillomavirus associated diseases comprising administering pharmaceutical compositions containing AAV Rep78 mutants or the DNA sequences encoding the mutants. Also discloses are DNA sequences comprising the full length AAV genome modified to where the AAV Rep78 protein is replaced with an AAV Rep mutant that binds weakly or not at all to a papillomavirus DNA or an AAV DNA or both differently as compared to the wild-type AAV Rep78 protein and its use in producing recombinant AAV at increased levels production over wild-type levels of production. Further disclosed is a method of inhibiting papillomavirus-associated diseases, cancer, and HIV-associated diseases comprising administering a pharmaceutical composition comprising a wild-type AAV Rep78 or a mutant thereof to a patient afflicted with a papillomavirus-associated disease, cancer, or HIV-associated diseases. Particularly, useful in treating papillomavirus-associated diseases are the AAV Rep78 or mutant thereof that binds to nucleotides 14-56 of p97 of HPV-16 and inhibits expression of HPV oncoproteins. An AAV Rep78 regulation element of a DNA sequence comprising about nucleotides 14-56 of the nucleotide sequence of FIG. 2 and an AAV Rep78 regulatable promoter comprising the regulation element and a promoter sequence except for the HPV-16 p97 promoter.
    • 10. 发明授权
    • Method of producing infectious papillomavirus in placental cells
    • 在胎盘细胞中产生感染性乳头状瘤病毒的方法
    • US06495361B1
    • 2002-12-17
    • US09621579
    • 2000-07-21
    • Paul L. HermonatYong Liu
    • Paul L. HermonatYong Liu
    • C12N700
    • C12Q1/708A61K39/00C12N7/00C12N2710/20051G01N2333/025
    • The present invention is discloses an improved method of producing infectious papillomavirus in vitro, with a method comprising (a) introducing papillomavirus or papillomavirus DNA or portions thereof necessary for replication, into an epithelial cell; and (b) providing conditions that produce papillomavirus, wherein the conditions comprise not contacting the epithelial cell a fibroblast and does not comprise an organotypic raft culture or a dermal equivalent. The present invention also discloses a papillomavirus infected non-keratinocyte epithelial cell produced by the methods of the present invention. Further, uses of the disclosed method includes detection methods, methods for screening anti-papillomavirus drugs, methods of making recombinant papillomavirus for vaccines and studying the life cycle. Additionally, a method of reducing and assessing the risk of spontaneous abortion is disclosed.
    • 本发明公开了一种在体外产生感染性乳头瘤病毒的改进方法,其方法包括(a)将乳头状瘤病毒或乳头瘤病毒DNA或其复制所必需的部分引入上皮细胞; 和(b)提供产生乳头瘤病毒的条件,其中所述条件不包括使上皮细胞与成纤维细胞接触,并且不包括器官型筏培养物或皮肤等效物。 本发明还公开了通过本发明的方法生产的乳头瘤病毒感染的非角化细胞上皮细胞。 此外,所公开的方法的用途包括检测方法,用于筛选抗乳头状瘤病毒药物的方法,制备用于疫苗的重组乳头瘤病毒的方法和研究生命周期。 另外,公开了减少和评估自然流产风险的方法。